| An update of safety of clinically used atypical antipsychotics L Orsolini, C Tomasetti, A Valchera, R Vecchiotti, I Matarazzo, F Vellante, ... Expert opinion on drug safety 15 (10), 1329-1347, 2016 | 134 | 2016 |
| Serotonin–glutamate and serotonin–dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic … A de Bartolomeis, EF Buonaguro, F Iasevoli Psychopharmacology 225, 1-19, 2013 | 103 | 2013 |
| Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to … A de Bartolomeis, R Balletta, S Giordano, EF Buonaguro, G Latte, ... Psychiatry research 210 (2), 387-395, 2013 | 97 | 2013 |
| Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and … A de Bartolomeis, C Sarappa, EF Buonaguro, F Marmo, A Eramo, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 46, 1-12, 2013 | 74 | 2013 |
| Treating the synapse in major psychiatric disorders: the role of postsynaptic density network in dopamine-glutamate interplay and psychopharmacologic drugs molecular actions C Tomasetti, F Iasevoli, EF Buonaguro, D De Berardis, M Fornaro, ... International Journal of Molecular Sciences 18 (1), 135, 2017 | 66 | 2017 |
| Affective temperaments are associated with specific clusters of symptoms and psychopathology: a cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or … F Iasevoli, A Valchera, E Di Giovambattista, M Marconi, MP Rapagnani, ... Journal of affective disorders 151 (2), 540-550, 2013 | 59 | 2013 |
| Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder M Mereu, G Contarini, EF Buonaguro, G Latte, F Managò, F Iasevoli, ... Neuropharmacology 121, 179-194, 2017 | 58 | 2017 |
| The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment F Iasevoli, C Tomasetti, E F Buonaguro, A de Bartolomeis Current neuropharmacology 12 (3), 219-238, 2014 | 55 | 2014 |
| The emerging role of dopamine–glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: implications for treatment A de Bartolomeis, EF Buonaguro, F Iasevoli, C Tomasetti Journal of psychopharmacology 28 (6), 505-526, 2014 | 49 | 2014 |
| Immediate-early genes modulation by antipsychotics: translational implications for a putative gateway to drug-induced long-term brain changes A De Bartolomeis, EF Buonaguro, G Latte, R Rossi, F Marmo, F Iasevoli, ... Frontiers in behavioral neuroscience 11, 240, 2017 | 47 | 2017 |
| Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol A de Bartolomeis, F Marmo, EF Buonaguro, R Rossi, C Tomasetti, ... European Neuropsychopharmacology 23 (11), 1516-1529, 2013 | 39 | 2013 |
| Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews M Fornaro, D De Berardis, G Perna, M Solmi, N Veronese, L Orsolini, ... BioMed Research International 2017 (1), 3084859, 2017 | 37 | 2017 |
| New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine L Orsolini, C Tomasetti, A Valchera, F Iasevoli, EF Buonaguro, F Vellante, ... Expert Review of Neurotherapeutics 16 (5), 483-495, 2016 | 37 | 2016 |
| The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions M Fornaro, M Solmi, N Veronese, D De Berardis, EF Buonaguro, ... International Review of Psychiatry 29 (5), 425-435, 2017 | 36 | 2017 |
| Current and future perspectives on the major depressive disorder: focus on the new multimodal antidepressant vortioxetine L Orsolini, C Tomasetti, A Valchera, F Iasevoli, EF Buonaguro, M Fornaro, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2017 | 36 | 2017 |
| Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles … A de Bartolomeis, F Iasevoli, F Marmo, EF Buonaguro, A Eramo, R Rossi, ... European Neuropsychopharmacology 25 (4), 566-582, 2015 | 30 | 2015 |
| COVID-19 and intellectual disability/autism spectrum disorder with high and very high support needs: issues of physical and mental vulnerability EF Buonaguro, MO Bertelli Advances in Mental Health and Intellectual Disabilities 15 (1), 8-19, 2021 | 21 | 2021 |
| Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review F Iasevoli, A Barone, EF Buonaguro, L Vellucci, A de Bartolomeis Expert Opinion on Drug Safety 19 (11), 1419-1444, 2020 | 21 | 2020 |
| Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling EF Buonaguro, F Iasevoli, F Marmo, A Eramo, G Latte, C Avagliano, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 76, 29-41, 2017 | 20 | 2017 |
| MicroRNAs in schizophrenia: implications for synaptic plasticity and dopamine–glutamate interaction at the postsynaptic density. New avenues for antipsychotic treatment under a … A de Bartolomeis, F Iasevoli, C Tomasetti, EF Buonaguro Molecular neurobiology 52, 1771-1790, 2015 | 19 | 2015 |
